Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James maintains a Neutral rating on Amedisys (NASDAQ:AMED) and raises the price target from $100 to $101.
September 14, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst maintains a Neutral rating on Amedisys and raises the price target from $100 to $101.
The news directly pertains to Amedisys (AMED) as Cantor Fitzgerald analyst Sarah James maintains a Neutral rating on the company and raises the price target from $100 to $101. This suggests that the analyst sees potential in the company but also acknowledges risks. This could lead to a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100